Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 14, 2020

View Archived Issues

Just the vesicles, please

Monocytes have it both ways in DMD

A role for DICER1 deficiency in retinal pigmented epithelium degeneration and neovascularization

New simulation approach for prediction of nanomedicine transport and distribution in animal species

PI4KIIIb-dependent secretion plays a role in the progression of chromosome 1q-amplified cancers

Enrolment update for phase III study of emixustat in Stargardt disease

Phase I study of brilacidin for ulcerative colitis meets primary endpoints

Discovery of new PROTAC with improved PK properties

First-in-human data presented for m102.4

Modified cyclodextrins show promising activity against multiple viral infections

Phase I/II data presented for SHR-3680 in metastatic castration-resistant prostate cancer

Focused ultrasound enhances BBB delivery of TrkA receptor ligands for treating neurodegeneration

Role of microglia in memory loss elucidated

MedImmune presents phase I data on MEDI-3726 in patients with mCRPC

IMP-4297 studied in phase III as maintenance treatment for advanced ovarian cancer

XyloCor begins first-in-human study of XC-001 gene therapy for refractory angina

Arcus Biosciences divulges adenosine A2A and/or A2B receptor antagonists

Fujifilm describes new compounds for adenovirus infections

BioBlocks and Visionary Pharmaceuticals disclose SGK1 inhibitors

Cocrystal Pharma identifies influenza PB2 inhibitors

Arbutus Biopharma synthesizes new compounds for HBV

Zhittya cleared to begin phase I study in Mexico with novel biological drug for Parkinson's

Eisai to withdraw Belviq from U.S. market

China NMPA approves Tecentriq with chemotherapy for extensive-stage SCLC

Japanese P-DRIVE study of polatuzumab vedotin in DLBCL meets primary endpoint

Phase II study of ANVS-401 in Alzheimer's cleared by DSMB to continue

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 27, 2026.
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
Sichuan Kelun Pharmaceutical Research Institute discovers GPR6 inverse agonists
BioWorld Science
Sichuan Kelun Pharmaceutical Research Institute Co. Ltd. has identified G protein-coupled receptor 6 (GPR6) inverse agonists reported to be useful for the...
Pharma industry faces long haul to get return on investment from AI
BioWorld Science
Artificial intelligence tools are springing up at multiple points along drug discovery and development, but despite the hype, as yet there is minimal return on...